Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sarsagenin (also known as sarsasapogenin or PYM50018) is a plant-derived steroidal sapogenin and the aglycone portion of certain plant saponins. It is found in species such as Dioscorea collettii (yam), Trigonella foenum-graecum (fenugreek), Anemarrhena asphodeloides (Zhi Mu), and Smilax species. Sarsagenin has attracted pharmaceutical interest for its neuroprotective properties; preclinical studies have shown that it protects against neuronal damage, increases neurite outgrowth, reverses oxidative damage and neuronal apoptosis. It is being investigated primarily for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and glaucoma[2][3]. Mechanistically, in vitro data suggest inhibition of organic anion transporting polypeptides OATP1B1 and OATP1B3[9]. Sarsagenin also serves as a precursor in the synthesis of other steroids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sarsagenin.